NCT05907954
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05907954
Title (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors IDEAYA Biosciences
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | FRA | DEU | CAN | AUS

Facility Status City State Zip Country Details
HonorHealth Research Institute Scottsdale Arizona 85258 United States Details
Moores Cancer Center La Jolla California 92093 United States Details
Stanford Cancer Institute Palo Alto California 94305 United States Details
University of Miami Miami Florida 33146 United States Details
The Cancer and Hematology Centers Grand Rapids Michigan 49546 United States Details
Mayo Clinic Rochester Rochester Minnesota 55905 United States Details
Northwell Manhasset New York 11030 United States Details
Thomas Jefferson University Philadelphia Pennsylvania 19107 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
University of Texas Southwestern Medical Center Dallas Texas 75390 United States Details
St. Vincent's Health Sydney Sydney New South Wales 2010 Australia Details
Alfred Health Melbourne Victoria 3004 Australia Details
Princess Margaret Cancer Centre Toronto Ontario M5G2M9 Canada Details
Institute Curie Paris 75005 France Details
Charité - Universitätsmedizin Berlin Berlin 12203 Germany Details
Fondazione IRCCS Istituto Nazionale Tumori Milan 20133 Italy Details
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome 00168 Italy Details
Leiden University Medical Center Leiden 2333 ZA Netherlands Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field